 MIAMI, Sept. 23, 2021 PRNewswire -- Big Cypress Acquisition Corp NASDAQ: BCYP, Big Cypress a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, today announced that it will hold a Special Meeting of stockholders the Special Meeting to, among other matters, allow its stockholders to approve the proposed business combination the Business Combination with SAB Biotherapeutics, Inc., SAB, a clinical-stage biopharmaceutical company developing a novel immunotherapy platform producing targeted, high potency, fully-human polyclonal antibody therapeutics and advancing programs in infectious disease, immune system disorders and oncology. 